Xenon Plans Q1 2027 Azetukalner Study With $1.2 Billion in Cash and Securities
Image: TokenPost
Xenon Pharmaceuticals plans to begin a Phase 3b/4 study of azetukalner in Q1 2027 as it pursues U.S. approval for focal seizures after filing a new drug application in Q3 2026. Xenon ended Q3 with $1.2 billion in cash, cash equivalents and marketable securities. The company expects those resources to fund operations into 2029 under current plans. Xenon expects topline results from X-NOVA2, a study in major depressive disorder (MDD), in December 2026. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.
Read the full story on TokenPostBeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.
